Purpose: To investigate the clinical efficacy of bevacizumab combined with gemcitabine and cisplatin (GP) combination chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: A total of 186 patients with advanced NSCLC who were admitted to the First Affiliated Hospital of Kunming Medical University from October 2013 to June 20/6 were randomly divided into control group and observation group, with 93 cases in each group. Patients in the control group were treated with GP chemotherapy, while patients in observation group were treated with intravenous infusion of bevacizumab combined with GP chemotherapy. Treatment was administered for 3 courses, every 3 weeks. After treatment, clinical efficacy, tumor markers levels (CEA and CYFRA21-1), serum vascular endothelial growth factor (VEGF) levels and adverse reactions were compared between two groups. Results: After treatment, the total effective rate and disease control rate in the control group were 40.86% and 70.97%, respectively, while the total effective rate and disease control rate in the observation group were 70.97% and 90.32% respectively, (p<0.05). After treatment, the levels of CEA, CY-FRA21-1 and serum VEGF in both groups were significantly lower than those before treatment (p<0.05), and decreases were more significant in the observation group than in the control group (p<0.05). The overall 1-, 3- and 5-year survival rates were 52.69% (49 cases), 36.56% (34 cases) and 25.81% (24 cases) for the observation group, and 43.01% (40 cases), 27.96% (26 cases) and 15.05 % (14 cases) for the control group. Overall survival rate in the observation group was significantly higher than the one in the control group (p<0.05). Conclusion: The combination of bevacizumab plus GP chemotherapy for advanced NSCLC can improve serum tumor markers and clinical efficacy, thus prolonging the long-term survival of patients. It is worthy of clinical application.